Phase Ia single center, randomized, double-blind, placebo-controlled, single and multiple ascending dose study evaluating the safety, tolerability, pharmacokinetics and the effects of food on AC-101
Latest Information Update: 05 Mar 2025
At a glance
- Drugs AC-101-Accropeutics (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 05 Mar 2025 New trial record